NemaMetrix becomes the first “Most Innovative” health startup at Demo Day!
NemaMetrix Inc. is the winner of the first “Most Innovative” health startup at Demo Day organized by CBInsights.
DD News features NemaMetrix in its latest issue on Animal Models of Disease
The latest issue of Drug Discovery News (DDNews) features a special report on Animal Models of Disease, highlighting the NemaMetrix/Knudra merger and the value of C. elegans as a model organism for disease research.
Unlocking the Potential of C. elegans for the Study of Rare Disease
Dr. Andy Golden at NIH discusses his work on identifying regulators and interactors of conserved genes in C. elegans that, when mutated, can cause human disease and opportunities to use C. elegans as a model in clinical and translational research.
Scientists study how cancer spreads by recording a time-lapse of C. elegans
Scientists from Duke University captured the cellular break-ins in C. elegans, a transparent worm that’s often used as a model for human biology. The cellular invasions are a normal part of the body’s development — but in cancer cells, the process goes haywire and leads to metastasis.
NemaMetrix and Knudra Transgenics announce merger
NemaMetrix and Knudra Transgenics announce merger to provide fast genotype-to-phenotype answers. The combined company will operate under NemaMetrix Inc.